CereAAV.YN

CereAAV.YN is an engineered adeno-associated virus (AAV) vector derived from the AAV2 serotype, developed by Takara Bio for the treatment of central nervous system (CNS) disorders. It was created by introducing specific amino acid substitutions into the CereAAV capsid, a variant identified through directed evolution of a random peptide-inserted AAV2 library. CereAAV.YN is designed to cross the blood-brain barrier (BBB) efficiently following systemic administration, addressing the limitations of traditional AAV2 vectors that require invasive direct intracerebral injection. Preclinical studies in mouse models demonstrated a 240-fold increase in gene transduction compared to AAV9, and studies in non-human primates (Cynomolgus macaques) showed successful gene delivery to over 70% of neuronal cells in the brain and spinal cord.